{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:05:11Z","timestamp":1793412311087,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.jaut.2015.06.005","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T09:10:01Z","timestamp":1436346601000},"page":"67-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":208,"special_numbering":"C","title":["Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: Multicenter study of 124 patients"],"prefix":"10.1016","volume":"62","author":[{"given":"H.","family":"Vallet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Riviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Deroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Moulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Addimanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bielefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Seve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jl","family":"Pasquali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jb","family":"Fraison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Marie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Perard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Schoindre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Le Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Papo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Resche","family":"Rigon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2015.06.005_bib1","first-page":"1078","article-title":"International study group for Beh\u00e7et\u2019s disease","volume":"335","author":"Anon Criteria for diagnosis of Beh\u00e7et\u2019s disease","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2015.06.005_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The international criteria for Beh\u00e7et\u2019s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD)","year":"2014","journal-title":"J.\u00a0Eur. Acad. Dermatol Venereol."},{"key":"10.1016\/j.jaut.2015.06.005_bib3","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.27568","article-title":"Mortality in Beh\u00e7et\u2019s disease","volume":"62","author":"Saadoun","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.06.005_bib4","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.06.005_bib5","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","article-title":"Management of Beh\u00e7et disease: a systematic literature review for the European league against Rheumatism evidence-based recommendations for the management of Beh\u00e7et disease","volume":"68","author":"Hatemi","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.06.005_bib6","first-page":"1544","article-title":"Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et\u2019s disease. A comparative study with familial mediterranean fever and healthy subjects","volume":"20","author":"Mege","year":"1993","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2015.06.005_bib7","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1186\/ar3824","article-title":"Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Beh\u00e7et\u2019s disease","volume":"14","author":"Sugita","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2015.06.005_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.06.005_bib9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jaut.2015.06.005_bib10","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.06.005_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et\u2019s disease","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.jaut.2015.06.005_bib12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","article-title":"Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects","volume":"1110","author":"Tognon","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jaut.2015.06.005_bib13","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2015.06.005_bib14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/bjophthalmol-2012-302515","article-title":"Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis","volume":"97","author":"Sakai","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jaut.2015.06.005_bib15","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","article-title":"Adalimumab for the treatment of Beh\u00e7et\u2019s disease: experience in 19 patients","volume":"51","author":"Perra","year":"2012","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2015.06.005_bib16","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et\u2019s disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2015.06.005_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","article-title":"Infliximab for the treatment of neuro-Beh\u00e7et\u2019s disease: a case series and review of the literature","volume":"59","author":"Pipitone","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.06.005_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","article-title":"Effect of infliximab in progressive neuro-Beh\u00e7et\u2019s syndrome","volume":"272","author":"Kikuchi","year":"2008","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.jaut.2015.06.005_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-009-1213-z","article-title":"One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh\u00e7et\u2019s disease refractory to standard immunosuppressive drugs","volume":"31","author":"Giardina","year":"2011","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jaut.2015.06.005_bib20","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2169\/internalmedicine.52.0589","article-title":"Efficacy of infliximab in patients with intestinal Beh\u00e7et\u2019s disease refractory to conventional medication","volume":"52","author":"Kinoshita","year":"2013","journal-title":"Intern Med. Tokyo Jpn."},{"key":"10.1016\/j.jaut.2015.06.005_bib21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3109\/s10165-010-0370-y","article-title":"Efficacy of combination therapy of anti-TNF-\u03b1 antibody infliximab and methotrexate in refractory entero-Beh\u00e7et\u2019s disease","volume":"21","author":"Iwata","year":"2011","journal-title":"Mod. Rheumatol. Jpn. Rheum. Assoc."},{"key":"10.1016\/j.jaut.2015.06.005_bib22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/ard.2005.045195","article-title":"Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment","volume":"65","author":"Baki","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.06.005_bib23","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.semarthrit.2011.02.006","article-title":"Resolution of Beh\u00e7et\u2019s syndrome associated pulmonary arterial aneurysms with infliximab","volume":"41","author":"Schreiber","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.06.005_bib24","first-page":"S94","article-title":"Infliximab for life-threatening pulmonary artery aneurysms in Beh\u00e7et\u2019s disease. A case report","volume":"29","author":"Tolosa-Vilella","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2015.06.005_bib25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.jaut.2015.06.005_bib26","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/art.38351","article-title":"Long-term outcome of Neuro-Beh\u00e7et\u2019s disease","volume":"66","author":"Noel","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2015.06.005_bib27","first-page":"5","article-title":"Efficacy of infliximab in refractory Beh\u00e7et\u2019s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients","volume":"6","author":"Cantini","year":"2012","journal-title":"Biol. Targets Ther."},{"key":"10.1016\/j.jaut.2015.06.005_bib28","series-title":"Anti-TNF-\u03b1 Therapy in Patients with Refractory Uveitis Due to Beh\u00e7et\u2019s Disease: a 1-year Follow-up Study of 124 Patients","author":"Calvo-R\u00edo","year":"2014"},{"key":"10.1016\/j.jaut.2015.06.005_bib29","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Gelder RN Van. expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaut.2015.06.005_bib30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/rheumatology\/40.4.473","article-title":"Treatment of recalcitrant orogenital ulceration of Beh\u00e7et\u2019s syndrome with infliximab","volume":"40","author":"Robertson","year":"2001","journal-title":"Rheumatol. Oxf Engl."},{"key":"10.1016\/j.jaut.2015.06.005_bib31","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/ard.2003.010975","article-title":"Successful treatment of genital ulcers with infliximab in Behcet's disease","volume":"63","author":"Haugeberg","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.06.005_bib32","first-page":"S99","article-title":"Infliximab for the treatment of resistant oral ulcers in Beh\u00e7et\u2019s disease: a case report and review of the literature","volume":"25","author":"Almoznino","year":"2007","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2015.06.005_bib33","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1365-2133.2005.06914.x","article-title":"Infliximab treatment for severe orogenital ulceration in Beh\u00e7et\u2019s disease","volume":"153","author":"Connolly","year":"2005","journal-title":"Br. J. Dermatol"},{"key":"10.1016\/j.jaut.2015.06.005_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3904\/kjim.2007.22.1.24","article-title":"Remission of intestinal Beh\u00e7et\u2019s disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab)","volume":"22","author":"Lee","year":"2007","journal-title":"Korean J. Intern Med."},{"key":"10.1016\/j.jaut.2015.06.005_bib35","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kep126","article-title":"Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet\u2019s disease","volume":"48","author":"Iwata","year":"2009","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2015.06.005_bib36","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.crohns.2011.03.006","article-title":"Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease","volume":"5","author":"De Cassan","year":"2011","journal-title":"J.\u00a0Crohns Colitis"},{"key":"10.1016\/j.jaut.2015.06.005_bib37","first-page":"774","article-title":"Clinical efficacy of adalimumab for a postoperative marginal ulcer in gastrointestinal Beh\u00e7et disease","volume":"109","author":"Shimizu","year":"2012","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.jaut.2015.06.005_bib38","first-page":"181","article-title":"Successful treatment of long-standing neuro-Beh\u00e7et\u2019s disease with infliximab","volume":"32","author":"Sarwar","year":"2005","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.jaut.2015.06.005_bib39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.2006.056804","article-title":"Successful treatment of refractory neuro-Behcet\u2019s disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile","volume":"66","author":"Fujikawa","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.06.005_bib40","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.2006.064279","article-title":"Adalimumab: a new modality for Beh\u00e7et\u2019s disease?","volume":"66","author":"Laar","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.06.005_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clineuro.2006.11.002","article-title":"A\u00a0patient with neuro-Beh\u00e7et\u2019s disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade","volume":"109","author":"Alty","year":"2007","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jaut.2015.06.005_bib42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10067-009-1272-2","article-title":"Adalimumab treatment for life threatening pulmonary artery aneurysm in Beh\u00e7et disease: a case report","volume":"29","author":"Lee","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2015.06.005_bib43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/acr.21557","article-title":"Beh\u00e7et\u2019s disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis","volume":"64","author":"Adler","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2015.06.005_bib44","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in the management of Behcet's disease\u2013review and basis for recommendations","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.jaut.2015.06.005_bib45","first-page":"413","article-title":"Effects of adalimumab administration in bio-na\u00efve and bio-switch rheumatoid arthritis patients in daily clinical practice\u202f: two-year results from single center","volume":"104","author":"Tashiro","year":"2013","journal-title":"Fukuoka Igaku Zasshi"},{"key":"10.1016\/j.jaut.2015.06.005_bib46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/01.MIB.0000438248.14218.1d","article-title":"Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory crohn's disease","volume":"20","author":"Brandse","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jaut.2015.06.005_bib47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2015.06.005_bib48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jcpt.12148","article-title":"Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events","volume":"39","author":"Mendes","year":"2014","journal-title":"J.\u00a0Clin. Pharm. Ther."},{"key":"10.1016\/j.jaut.2015.06.005_bib49","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jcpt.12045","article-title":"Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis","volume":"38","author":"F\u00e9nix-Caballero","year":"2013","journal-title":"J.\u00a0Clin. Pharm. Ther."},{"key":"10.1016\/j.jaut.2015.06.005_bib50","first-page":"71","article-title":"Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR)","volume":"32","author":"Westhovens","year":"2014","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841115000876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841115000876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:11:18Z","timestamp":1760256678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841115000876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":50,"alternative-id":["S0896841115000876"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2015.06.005","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: Multicenter study of 124 patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2015.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}